Governors Lane’s Akebia Therapeutics AKBA Stock Holding History

Governors Lane’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-25,900	Closed	-$229K	–	73
2018 Q3	$229K	Buy	+25,900	New	+$232K	0.01%	78

Other funds holding AKBA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Governors Lane's AKBA Position: Q4 2018 in Review

Governors Lane sold out of Akebia Therapeutics (AKBA) in Q4 2018, closing a stake of 25,900 shares — an estimated $229K sold.

Governors Lane first reported a position in AKBA in Q3 2018 and held it in 1 quarter. The position peaked at $229K in Q3 2018. 166 funds tracked by Wall St. Rank hold AKBA as of Q4 2018.

Governors Lane reported no remaining Akebia Therapeutics position as of Q4 2018 after selling out during the quarter.
Governors Lane sold 25,900 Akebia Therapeutics shares in Q4 2018, an estimated $229K.
Governors Lane first reported a position in Akebia Therapeutics in Q3 2018 and held it in 1 quarter.
Governors Lane's Akebia Therapeutics position peaked at $229K in Q3 2018.
166 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2018.

Based on Governors Lane's 13F filing for Q4 2018, filed 14 Feb 2019.